Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vistagen Therapeutics, Inc. - Common Stock
(NQ:
VTGN
)
0.5056
-0.0394 (-7.23%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vistagen Therapeutics, Inc. - Common Stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Closing of Strategic Acquisition
February 02, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
February 02, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Doses First Participants in PH10 Phase 1 Clinical Trial
January 24, 2023
Via
Investor Brand Network
VistaGen Therapeutics Earnings Perspective: Return On Capital Employed
↗
December 22, 2022
Via
Benzinga
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
January 31, 2023
Gainers
Via
Benzinga
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
January 24, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Set to Commence Antidepressant Nasal Spray Trial This Quarter
January 19, 2023
Via
Investor Brand Network
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
January 19, 2023
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
Via
News Direct
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
January 19, 2023
By Rachael Green, Benzinga
Via
TheNewswire.com
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023
↗
January 17, 2023
In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ: VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major...
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Completes 4-Week Treatment Protocol for Final Patient in Phase 2 AjDA Trial
January 10, 2023
Via
Investor Brand Network
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
January 10, 2023
From
Vistagen
Via
Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Takes Key Steps to Protect, Enhance IP Program
January 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
December 30, 2022
From
Vistagen
Via
Business Wire
Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket
↗
December 29, 2022
Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the...
Via
Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Acquire Pherin Pharmaceuticals Inc.
December 21, 2022
Via
Investor Brand Network
Vistagen Strengthens Its Neurology Focused Pipeline With Pherin Pharma Acquisition
↗
December 21, 2022
Via
Benzinga
Vistagen to Acquire Pherin Pharmaceuticals
December 21, 2022
From
Vistagen
Via
Business Wire
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
↗
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
December 19, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
December 19, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
December 16, 2022
Via
Benzinga
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
December 16, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
December 13, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
December 06, 2022
Via
Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces FDA Fast Track Designation for Development of Proprietary MDD Treatment
December 06, 2022
Via
Investor Brand Network
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
↗
December 06, 2022
Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific...
Via
Benzinga
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
December 06, 2022
From
Vistagen
Via
Business Wire
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
November 30, 2022
From
Vistagen
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 29, 2022
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
